480 Arsenal Way
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
66 articles with Selecta Biosciences
Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19 at 1:50 p.m. Eastern Time.
Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to issue its third quarter 2019 financial results on Friday November 8, 2019.
Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that data from the company’s completed Phase 2 dose ranging study of SEL-21 (NCT02959918) for the treatment of chronic refractory gout will be presented at the upcoming 2019 American College of Rheumatology (ACR) Annual Meeting being held from November 8-13, 2019 in Atlanta, GA.
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today presented new preclinical data from its gene therapy program at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress from October 22-25, 2019 in Barcelona, Spain.
7/19/2019Pharma and biotech companies from across the globe expand their leadership teams and boards.
Alison is an extremely accomplished senior leader with over 20 years of combined drug development, strategic management and practical clinical experience in academia and industry, successfully leading multiple clinical programs to approval
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
To accelerate the commercialization of life-changing products, bioscience companies are selecting Oracle NetSuite.
Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage trial that showed a significant reduction of serum uric acid at 12 weeks.
Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in PNAS Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined With SVP-Rapamycin
In the PNAS publication, the authors described preclinical work in which SVP-Rapamycin mitigated the formation of inhibitory ADAs to LMB-100 in both naïve mice and mice pre-exposed to LMB-100, resulting in restoration of LMB-100’s anti-tumor activity.
Selecta Biosciences Announces FDA Acceptance of IND Application for LMB-100 and SVP-Rapamycin Com...
1/2/2018SVP-Rapamycin is Selecta’s proprietary, clinical-stage anti-drug antibody (ADA) prevention and immune tolerance technology.
Werner Cautreels, Ph.D., intends to retire effective December 31, 2018.
For the third quarter of 2017, the company’s total revenue was less than $0.1 million, which compares with $1.0 million for the third quarter of 2016.
Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
t 8:30 a.m. ET that day, Selecta will host a conference call to discuss these results and provide a corporate update.
The company announced two additions to its management team today.